Today: 17 March 2026
Subscribe
Browse Category

ASX:TNO 18 December 2025 - 23 February 2026

ASX 200 today: Australia shares seen softer after tariff uncertainty jars banks, tech

ASX 200 today: Australia shares seen softer after tariff uncertainty jars banks, tech

ASX 200 futures traded around 8,988 early Tuesday, about 0.4% below Monday’s close after the index fell 0.61% on U.S. tariff uncertainty. Growth stocks and banks dropped, while resources and gold miners outperformed. The Australian dollar slipped 0.2% to 70.68 U.S. cents. Traders await January inflation data due Wednesday.
23 February 2026
········
Australia stock market jumps as miners rally, tech gets slammed; Xero sinks

Australia stock market jumps as miners rally, tech gets slammed; Xero sinks

Australia’s S&P/ASX 200 closed up 0.8% at 8,927, lifted by miners and energy stocks as materials surged 3.6%. Technology shares plunged, with Xero down 15.9% and WiseTech Global off 10.7%. The Reserve Bank raised rates by 25 basis points to 3.85%, its first hike in two years. Neuren Pharmaceuticals entered a trading halt.
4 February 2026
········
Top ASX Stocks to Buy Today (18 December 2025): Lithium Upgrades, Gold Surge, and Woodside in Focus

Top ASX Stocks to Buy Today (18 December 2025): Lithium Upgrades, Gold Surge, and Woodside in Focus

The S&P/ASX 200 fell 0.16% by 10:21am AEDT as tech stocks extended losses for an eighth session, mirroring a 1.4% drop in the Nasdaq overnight. Lithium futures in China jumped nearly 8%, with broker upgrades boosting local lithium stocks. Spot gold traded near US$4,374/oz, and silver hit a record US$65.8/oz, lifting precious metals shares. Banks and miners remained steady.
18 December 2025
····

Stock Market Today

  • Agenus Q4 Earnings Exceed Estimates with $0.56 EPS and $34.2M Revenue
    March 16, 2026, 10:29 PM EDT. Agenus (AGEN) reported a quarterly earnings per share (EPS) of $0.56, significantly beating the Zacks Consensus Estimate loss of $1.27 and the previous year's $2.04 loss. This marked an earnings surprise of +144.27%. The biotechnology firm also posted revenues of $34.2 million, surpassing estimates by 17.54% and up from $26.84 million a year ago. Despite positive earnings and revenue surprises, Agenus stock has declined about 1.3% year-to-date, trailing the S&P 500's 3.1% drop. The company holds a Zacks Rank #3 (Hold), projecting in-line market performance ahead. Investors await management's commentary on the earnings call and future estimate revisions amid mixed consensus for upcoming quarters.
Go toTop